# LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer

> **NCT07453875** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 9 (estimated)

## Conditions studied

- Peritoneal Metastasis of Gastric and Colorectal Cancer
- LDRT

## Interventions

- **RADIATION:** LDRT
- **DRUG:** SOX or CAPOX regimen
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07453875
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07453875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07453875, "LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07453875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*